MX360030B - Metodos para tratar el trastorno bipolar. - Google Patents

Metodos para tratar el trastorno bipolar.

Info

Publication number
MX360030B
MX360030B MX2016002438A MX2016002438A MX360030B MX 360030 B MX360030 B MX 360030B MX 2016002438 A MX2016002438 A MX 2016002438A MX 2016002438 A MX2016002438 A MX 2016002438A MX 360030 B MX360030 B MX 360030B
Authority
MX
Mexico
Prior art keywords
bipolar disorder
methods
treating bipolar
treating
amide
Prior art date
Application number
MX2016002438A
Other languages
English (en)
Spanish (es)
Inventor
James Lee Sung
Marie Melnick Susan
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX360030B publication Critical patent/MX360030B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2016002438A 2010-06-30 2011-06-27 Metodos para tratar el trastorno bipolar. MX360030B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/827,505 US9610274B2 (en) 2010-06-30 2010-06-30 Methods for treating bipolar disorder
PCT/KR2011/004676 WO2012002687A2 (en) 2010-06-30 2011-06-27 Methods for treating bipolar disorder

Publications (1)

Publication Number Publication Date
MX360030B true MX360030B (es) 2018-10-19

Family

ID=45400168

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016002438A MX360030B (es) 2010-06-30 2011-06-27 Metodos para tratar el trastorno bipolar.
MX2012014686A MX2012014686A (es) 2010-06-30 2011-06-27 Metodos para tratar el transtorno bipolar.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012014686A MX2012014686A (es) 2010-06-30 2011-06-27 Metodos para tratar el transtorno bipolar.

Country Status (13)

Country Link
US (2) US9610274B2 (enExample)
EP (1) EP2590645B1 (enExample)
JP (1) JP5881692B2 (enExample)
KR (1) KR101828934B1 (enExample)
CN (1) CN102985085B (enExample)
AU (1) AU2011272156B2 (enExample)
BR (1) BR112012033738A2 (enExample)
CA (1) CA2801241C (enExample)
ES (1) ES2654615T3 (enExample)
MX (2) MX360030B (enExample)
PL (1) PL2590645T3 (enExample)
RU (1) RU2653408C2 (enExample)
WO (1) WO2012002687A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5024635B2 (ja) 2005-06-08 2012-09-12 エスケー バイオファーマスティカルズ カンパニー リミテッド 睡眠覚醒障害の治療
EP2445490B1 (en) 2009-06-22 2023-02-08 SK Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
TWI684450B (zh) 2013-03-13 2020-02-11 南韓商愛思開生物製藥股份有限公司 猝倒症之治療
PT3021838T (pt) 2013-07-18 2020-09-01 Sk Biopharmaceuticals Co Ltd Tratamento para a obesidade
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
EP4364794A3 (en) 2016-09-06 2024-07-24 Axsome Malta Ltd. Solvate form of (r)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
JP7074750B2 (ja) 2016-10-06 2022-05-24 ジャズ ファーマスティカルズ アイルランド リミテッド カルバモイルフェニルアラニノール化合物およびその使用
MY199104A (en) * 2016-12-14 2023-10-13 Sk Biopharmaceuticals Co Ltd Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
JP2020528075A (ja) 2017-06-02 2020-09-17 ジャズ ファーマシューティカルズ アイルランド リミテッド 過度の眠気を処置するための方法および組成物
SG11202000817SA (en) 2017-07-31 2020-02-27 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol analogs and uses thereof
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
AU2024308064A1 (en) 2023-06-29 2026-01-22 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260667A (en) 1993-06-10 1997-05-26 Lilly Co Eli Preventing emesis or treating sexual dysfunction using tetrahydrobenz[cd]indole 6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
CN1076016C (zh) 1996-10-10 2001-12-12 Sk株式会社 O－氨基甲酰基－苯丙胺醇化合物、其药学上有用的盐和它们的制备方法
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
TW548103B (en) 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
CN1118452C (zh) 1998-04-28 2003-08-20 大日本制药株式会社 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
EP1347971B1 (en) 2000-12-21 2006-03-01 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
ATE369130T1 (de) 2001-02-27 2007-08-15 Ortho Mcneil Pharm Inc Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
HUP0303236A3 (en) 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in the treatment of pain
EP1390034A4 (en) 2001-04-03 2005-07-13 Merck & Co Inc N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS
EP1399160A4 (en) 2001-06-12 2004-08-25 Merck & Co Inc NR2B RECEPTOR ANTAGONISTS FOR TREATING OR PREVENTING MIGRAINE
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
AU2003259482A1 (en) 2002-09-20 2004-04-08 Pfizer Japan Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
MXPA05011270A (es) 2003-04-21 2006-01-24 Pfizer Compuestos de imidazopiridina que tienen actividad agonista del receptor 5-ht4 y actividad antagonista del receptor 5-ht3.
BRPI0414105B8 (pt) 2003-09-03 2021-05-25 Askat Inc compostos de benzimidazolona com atividade agonista do receptor 5-ht4
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
KR20070083826A (ko) 2004-10-28 2007-08-24 에스케이 주식회사 우울증을 위한 부가 요법
MX2007012463A (es) 2005-04-08 2007-11-07 Pfizer Prod Inc Heteroarilamidas[3.1.0]biciclicas como inhibidores del transporte de glicina de tipo i.
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
JP5024635B2 (ja) * 2005-06-08 2012-09-12 エスケー バイオファーマスティカルズ カンパニー リミテッド 睡眠覚醒障害の治療
CA2612672C (en) 2005-06-22 2014-10-14 Janssen Pharmaceutica, N.V. Treatment for sexual dysfunction
ES2385087T3 (es) 2005-07-26 2012-07-18 Sk Biopharmaceuticals Co., Ltd Procedimientos para tratar trastornos relacionados con sustancias
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
BRPI0719275A2 (pt) 2006-10-13 2014-04-29 Janssen Pharmaceutica Nv Composições de carbamatos de fenil-alquil-amino
HUP0700370A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
EP2445490B1 (en) 2009-06-22 2023-02-08 SK Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101097605B1 (ko) 2009-11-04 2011-12-22 알.에프 에이치아이씨 주식회사 도허티 증폭기
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
RU2557533C2 (ru) 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome

Also Published As

Publication number Publication date
CA2801241C (en) 2018-07-17
EP2590645A2 (en) 2013-05-15
RU2653408C2 (ru) 2018-05-08
ES2654615T3 (es) 2018-02-14
US9907777B2 (en) 2018-03-06
KR101828934B1 (ko) 2018-03-29
BR112012033738A2 (pt) 2017-08-08
US20120004300A1 (en) 2012-01-05
WO2012002687A2 (en) 2012-01-05
EP2590645A4 (en) 2014-01-22
CN102985085A (zh) 2013-03-20
JP5881692B2 (ja) 2016-03-09
KR20130112706A (ko) 2013-10-14
RU2012155118A (ru) 2014-08-10
AU2011272156A1 (en) 2013-02-07
CA2801241A1 (en) 2012-01-05
US9610274B2 (en) 2017-04-04
MX2012014686A (es) 2013-02-11
AU2011272156B2 (en) 2015-02-12
EP2590645B1 (en) 2017-10-04
US20170151209A1 (en) 2017-06-01
CN102985085B (zh) 2018-10-02
PL2590645T3 (pl) 2018-03-30
WO2012002687A3 (en) 2012-04-26
JP2013533253A (ja) 2013-08-22

Similar Documents

Publication Publication Date Title
MX360030B (es) Metodos para tratar el trastorno bipolar.
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
WO2012002688A3 (en) Methods of treating restless legs syndrome
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
PH12015500719A1 (en) Gdf-8-inhibitors
UA110983C2 (uk) Похідна 1,2,3,4-тетрагідрохіноліну, придатна для лікування діабету
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX349159B (es) Derivados deuterados de ivacaftor.
PH12014501695A1 (en) Pde9 inhibitors with imidazo triazinone backbone
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
MX2015008187A (es) Inhibidores de alk deuterados.
MX2013012588A (es) Inhibidores de cinasa.
MY170922A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
PH12014500990A1 (en) Methods for treating gout flares
MX2012013740A (es) Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
EA201690327A1 (ru) Терапевтические способы
TW201129361A (en) Methods for treating pain
PH12014502065A1 (en) Vesicular formulations
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.